- Home
- GRX vs ZNTL Comparison
GRX vs ZNTL Comparison
Compare GRX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- ZNTL
- Stock Information
- Founded
- GRX 2007
- ZNTL 2014
- Country
- GRX United States
- ZNTL United States
- Employees
- GRX N/A
- ZNTL N/A
- Industry
- GRX Finance/Investors Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- ZNTL Health Care
- Exchange
- GRX Nasdaq
- ZNTL Nasdaq
- Market Cap
- GRX 142.7M
- ZNTL 118.3M
- IPO Year
- GRX N/A
- ZNTL 2020
- Fundamental
- Price
- GRX $9.23
- ZNTL $1.53
- Analyst Decision
- GRX
- ZNTL Buy
- Analyst Count
- GRX 0
- ZNTL 6
- Target Price
- GRX N/A
- ZNTL $6.53
- AVG Volume (30 Days)
- GRX 39.7K
- ZNTL 751.6K
- Earning Date
- GRX 01-01-0001
- ZNTL 11-06-2025
- Dividend Yield
- GRX 5.98%
- ZNTL N/A
- EPS Growth
- GRX N/A
- ZNTL N/A
- EPS
- GRX 0.26
- ZNTL N/A
- Revenue
- GRX N/A
- ZNTL $26,865,000.00
- Revenue This Year
- GRX N/A
- ZNTL N/A
- Revenue Next Year
- GRX N/A
- ZNTL N/A
- P/E Ratio
- GRX $38.50
- ZNTL N/A
- Revenue Growth
- GRX N/A
- ZNTL N/A
- 52 Week Low
- GRX $7.73
- ZNTL $1.01
- 52 Week High
- GRX $10.40
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- GRX 48.46
- ZNTL 43.89
- Support Level
- GRX $9.23
- ZNTL $1.50
- Resistance Level
- GRX $9.34
- ZNTL $1.82
- Average True Range (ATR)
- GRX 0.10
- ZNTL 0.10
- MACD
- GRX 0.01
- ZNTL -0.01
- Stochastic Oscillator
- GRX 46.61
- ZNTL 7.69
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.